Kamal Adawi

Companies

• Fate TherapeuticsChief financial officer Oct 21, 2025 to now⁶
• Exagen Inc.Chief financial officer Sep 18, 2019 to Sep 4, 2024⁷

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Exagen Inc. XGN243,749 shares⁸$1.8M at $7.40Mar 4, 2024
• FTFate Therapeutics FATE100,000 shares⁹$188.0K at $1.88Jan 15, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Jan 15, 2026Granted 25,000 shares of Fate Therapeutics⁹
• Oct 20, 2025Granted 75,000 shares of Fate Therapeutics¹⁰
• Mar 4, 2024Sold 3,487 shares at $1.91 of Exagen Inc.⁸
• Mar 4, 2024Sold 9,297 shares at $1.91 of Exagen Inc.⁸
• Feb 20, 2024Granted 75,000 shares of Exagen Inc.¹¹
• Feb 6, 2024Sold 6,738 shares at $1.95 of Exagen Inc.¹²
• Mar 2, 2023Sold 3,667 shares at $2.30 of Exagen Inc.¹³
• Feb 27, 2023Granted 100,000 shares of Exagen Inc.¹⁴
• Feb 8, 2023Sold 5,821 shares at $2.69 of Exagen Inc.¹⁵
• Mar 1, 2022Shares withheld for tax 3,241 shares at $7.12 of Exagen Inc.¹⁶
• Feb 4, 2022Granted 63,500 shares of Exagen Inc.¹⁷